Gopten (Trandolapril)

Gopten (trandolapril) is indicated for the oral treatment of several cardiovascular disorders.

• Management of essential hypertension.
• Treatment of chronic heart failure to improve symptoms and reduce hospitalizations.
• Post‑myocardial infarction therapy to attenuate ventricular remodeling.
• Adjunctive therapy in patients with diabetic nephropathy when prescribed by a specialist.

The safety profile of trandolapril includes both frequently observed and less common adverse events.

Common

• Persistent dry cough.
• Dizziness or light‑headedness, especially after the first dose.
• Headache.
• Fatigue or mild weakness.
• Transient hypotension.
• Elevated blood potassium levels.

Serious

• Angioedema involving the face, lips, tongue, or airway.
• Severe or symptomatic hypotension.
• Acute renal failure or significant rise in serum creatinine.
• Neutropenia or agranulocytosis.
• Hepatotoxicity presenting as jaundice or elevated liver enzymes.
• Hyperkalemia leading to cardiac arrhythmias.

Before initiating Gopten, clinicians should evaluate several clinical factors to minimize risk.

• Assess renal function and adjust dose in patients with moderate to severe impairment.
• Monitor serum potassium and avoid use in patients with hyperkalemia.
• Use with caution in patients with a history of angioedema related to ACE inhibitors.
• Contraindicated during the second and third trimesters of pregnancy (Category D).
• Review concomitant use of potassium‑sparing diuretics or supplements.
• Advise patients to rise slowly from sitting or lying positions to reduce orthostatic dizziness.
• Periodic liver function tests are recommended for long‑term therapy.

Trandolapril may interact with several medication classes, influencing its efficacy or safety.

Avoid

• Concurrent use with other ACE inhibitors, ARBs, or aliskiren in diabetic patients.
• Combination with potassium‑sparing diuretics or high‑dose potassium supplements.
• Use with non‑steroidal anti‑inflammatory drugs (NSAIDs) that may impair renal function.

Use with caution

• Dual therapy with diuretics may increase the risk of hypotension.
• Concomitant lithium therapy may raise lithium levels.
• Co‑administration with certain antidiabetic agents may require glucose monitoring.
• Interaction with rifampin or other enzyme inducers may reduce trandolapril plasma concentrations.